Abstract:The RAS family includes three RAS genes, which encode four highly homologous proteins: H-, N-, and KRAS4A and 4B, the latter two being alternatively spliced forms differing only at the carboxyl terminus. RAS oncogenic mutations, mostly KRAS and NRAS , are common in human cancers. Since the enzymatic activity of RAS is used to turn itself off and its GTP binding affinity is very high, RAS proteins have been difficult to target. Identification of alternative means to block the RAS oncogenic signaling is critical for developing therapies against RAS-driven cancer. We took a chemical biology approach to discover novel therapeutic strategies for RAS-related cancer. Since the biological activity of RAS proteins relies upon lipid modifications and RAS regulates lipid metabolisms in cancer cells, we used a RAS specific cell viability assay to screen a bioactive lipid library for potential therapeutics against RAS-driven cancer. We found that endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) could effectively kill RAS-transformed cells. The structure-activity analysis showed that the anti-RAS activity of NADA relied on both the dopamine and arachidonoyl moieties in the same molecule and was independent of its ability to engage cannabinoid or vanilloid receptors. Further analysis showed that NADA was more active in killing cells transformed by oncogenic NRAS or KRAS4A than that of KRAS4B. Consistently, NADA was more active in inhibiting the phosphorylation of ERK in NRAS-transformed cells than that in KRAS4B-transformed cells. Interestingly, NADA blocked the plasma membrane translocation of NRAS and KRAS4A, but not that of KRAS4B. Significant effect of NADA on palmitoylated NRAS levels was not detected, suggesting that NADA inhibits NRAS and KRAS4A plasma membrane translocation through a novel mechanism. These results demonstrate that NADA possesses a novel property of inhibiting the plasma membrane translocation and neoplastic transforming activity of NRAS and KRAS4A. Since NRAS mutations are common in hematological malignancies as well as in solid tumors such as melanoma and colorectal carcinoma, and KRAS4A is required for carcinogen-induced lung cancer, the new findings would help to develop novel therapies for a broad range of human cancers. Disclosures No relevant conflicts of interest to declare.

Simultaneous Activation of K-ras and NRF2 Induce Pancreatic Atrophy

NGF Upregulation in the Pancreas is Associated with Neurochemical Changes in Sensory Neurons in a Rat Model of Chronic Pancreatitis

Successive Treatment With Naltrexone Induces Epithelial-Mesenchymal Transition And Facilitates The Malignant Biological Behaviors Of Bladder Cancer Cells

Tu1660 HEPATIC P53-PXR-SCD1 AXIS PARTICIPATES IN NAFLD PROCESS

Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition

Nintedanib Alleviates Chronic Pancreatitis by Inhibiting the Activation of Pancreatic Stellate Cells via the JAK/STAT3 and ERK1/2 Pathways

Nrf2 promotes mutant K-ras/p53-driven pancreatic carcinogenesis

Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer.

Multilevel Regulation of NF‐κB Signaling by NSD2 Suppresses Kras‐Driven Pancreatic Tumorigenesis

Effects of Naltrexone on Expression of Lipid Metabolism-Related Proteins in Liver Steatosis Induced by Endoplasmic Reticulum Stress in Mice

Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation

Nuclear Factor Erythroid 2-Related Factor 2 Depletion Sensitizes Pancreatic Cancer Cells to Gemcitabine via Aldehyde Dehydrogenase 3a1 Repression

Application of the Targeted Next Generation Sequencing to the Comprehensive Analysis of Pancreatitis Susceptibility Genes

Low-Dose Sorafenib Acts As a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis

Abstract PR-09: Temporally resolved proteomics identifies nidogen-2 as a co-target in pancreatic cancer that modulates fibrosis and therapy response

Inhibition of Nicotinamide Phosphoribosyltransferase Protects Against Acute Pancreatitis Via Modulating Macrophage Polarization and Its Related Metabolites.

The extracellular niche and tumor microenvironment enhance KRAS inhibitor efficacy in pancreatic cancer.

The Endocannabinoid/Endovanilloid N-Arachidonoyl Dopamine Suppresses the Plasma Membrane Translocation and Neoplastic Transforming Activity of NRAS and KRAS4A

AXL and MERTK Receptor Tyrosine Kinases Inhibition Protects Against Pancreatic Necrosis Via Selectively Limiting CXCL2-related Neutrophil Infiltration

NAC Alleviative Ferroptosis in Diabetic Nephropathy Via Maintaining Mitochondrial Redox Homeostasis Through Activating SIRT3-SOD2/Gpx4 Pathway.

Overexpression of Nrf2 Protects Against Lipopolysaccharide and Cerulein-Induced Pancreatitis In Vitro and In Vivo.